INC Research’s Kendle acquisition vaulted the North Carolina clinical research organization into the CRO industry’s top five and, according to CEO James Ogle, helped the company become a global player.
Ogle spoke with Outsourcing Pharma, a British publication that covers the CRO industry. Audio of the Outsourcing Pharma interview can be heard here. In the interview, Ogle explains that the deal, first announced in April, helped expand the Raleigh, N.C.-based CRO’s geographic reach and also reinforce its capabilities in the top areas for drug development.
INC Research late last month closed on its $232 million acquisition of Cincinnati, Ohio-based CRO Kendle. At the beginning of June, it acquired Australia CRO Trident Clinical Research.
Ogle tells Outsourcing Pharma that Kendle brings INC Research a strong presence in Latin America and Asia while Trident brings to the company additional geographic breadth.
Ogle said that INC Research currently doesn’t have any plans for further acquisitions “in the near future.” But he leaves the door open for future acquisitions that bring the company a geographic or therapeutic capability it doesn’t currently have.
“One should never say never,” Ogle said.